Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.

Oncotarget - 14 Feb 2017

Bhatt Michelle, Ivan Cristina, Xie Xiaolei, Siddik Zahid H

Abstract excerpt

Cisplatin (cis-Pt) resistance in tumor cells from p53 dysfunction is a significant clinical problem. Although mutation can inhibit p53 function, >60% of p53 mutants retain normal function according to literature reports. Therefore, we examined the status of p53 in cisplatin-resistant ovarian tumor models and its functional response to cis-Pt and the mechanistically-distinct non-cross-resistant oxaliplatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 2
Share to Cisplatin
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Serine

Source

Open in PubMed Open full text

Identifiers

PMID: 28038466
DOI: 10.18632/oncotarget.14228
PMCID: PMC5355233

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.PMID 28038466Read ↗

Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.Semantic proximity Read ↗

A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.Semantic proximity Read ↗

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic ApproachesSemantic proximity Read ↗

Towards the overcoming of anticancer drug resistance mediated by p53 mutations.Semantic proximity Read ↗

Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.Semantic proximity Read ↗

Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to OxaliplatinSemantic proximity Read ↗

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.Semantic proximity Read ↗

p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells.Semantic proximity Read ↗

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell LinesSemantic proximity Read ↗

PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells.Semantic proximity Read ↗

The cellular pharmacology of oxaliplatin resistanceSemantic proximity Read ↗

Overcoming Cisplatin Resistance in TP53-null Colon Cancer OrganoidsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.